Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors - PubMed
a day ago
- #SGLT2 inhibitors
- #diabetes management
- #adverse events
- SGLT2 inhibitors (SGLT2i) are widely used for diabetes management and show benefits in treating heart failure (HF) and chronic kidney disease (CKD).
- Common adverse events include genital infections (GIs) in diabetic patients, while urinary tract infections (UTIs) show inconsistent associations.
- Non-diabetic HF/CKD patients experience modest increases in GIs and UTIs.
- SGLT2i may increase hematocrit and reveal clonal erythrocytosis.
- Rare cases like Fournier’s gangrene have been reported, leading to drug discontinuation.
- No conclusive evidence links SGLT2i to fractures or osteoporosis.
- Risk of lower-limb amputation is comparable to DPP-4 inhibitors, with caution advised for peripheral artery disease patients.
- Observational data suggest SGLT2i may protect against syncope and reduce acute kidney injury.
- Overall, SGLT2i are safe with manageable adverse events, requiring clinician awareness for optimal patient management.